

Informazioni personali

Nome Mario Colucci
Telefono Ufficio 080 5478471
e-mail mario.colucci@uniba.it
Nazionalità italiana
Data di Nascita 10/12/1952
Posizione accademica Professore associato di Patologia Generale
Abilitato alla prima fascia (tornata 2013)

Istruzione e formazione

Laurea in scienze Biologiche (AA 1976/77) presso l'università degli Studi di Bari (110/110)
Specializzazione in Ricerche Farmacologiche presso l'Istituto Mario Negri, Milano (1981)

Attività didattica

PATOLOGIA GENERALE – corso di laurea magistrale in Scienze Biosanitarie
Corso Integrato: PATOLOGIA E IMMUNOLOGIA - Corso di Laurea in Medicina e Chirurgia
Corso Integrato: SCIENZE DELLA PATOLOGIA UMANA - Corso di Laurea in Tecniche di Laboratorio Biomedico
PATOLOGIA CLINICA – Scuola di specializzazione in Patologia Clinica

Principali mansioni e responsabilità

Presidente della Scuola di Specializzazione in Patologia Clinica, Università di Bari “Aldo Moro” (2006-2013).
Membro del collegio del dottorato di ricerca SCIENZE BIOMOLECOLARI FARMACEUTICHE E MEDICHE

Cariche Scientifiche

Presidente dell'International Society of Fibrinolysis and Proteolysis (ISFP, 2016-2018)
Membro eletto del Comitato Direttivo dell'International Society of Fibrinolysis and Proteolysis (ISFP, 2002-2008)
Membro dell'Advisory Board dell' International Society of Fibrinolysis and Proteolysis (dal Luglio 2008).
Membro dell' advisory board della rivista “Journal of Thrombosis and Haemostasis” (2003-2007)
Membro dello “Scientific Committee” del XV International Congress on Thrombosis and Haemostasis, Firenze 6-12 Giugno 1997.

Membro del Consiglio direttivo della Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET)
Membro del Comitato Scientifico del XIX Congresso Nazionale della Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET), Milano, 14-17 Settembre 2006
Membro dello "Scientific Advisory Board" del XXth Congress of the International Society of Fibrinolysis and Proteolysis, Amsterdam, 24-28 Agosto 2010.
Membro dello "Scientific Advisory Board" del XXI Congress of the International Society of Fibrinolysis and Proteolysis, Brighton, 1-5 luglio, 2012.
Membro dello "Scientific Advisory Board" del XXII Congress of the International Society of Fibrinolysis and Proteolysis, Marseille, 6-9 Luglio 2014.
Membro dello "Scientific Advisory Board" del XXIII Congress of the International Society of Fibrinolysis and Proteolysis, Shizuoka, 17-21 ottobre 2016
Responsabile scientifico dell'11° Congresso Nazionale della Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET), Bari, 24-28 Settembre 1990.

Journal reviewer (dal 1986)

J Thromb Haemost, Thromb Haemost, Thromb Res, Arterioscler Thromb Vasc Biol, Biochim Biophys Acta, Blood, Circulation, Eur J Biochem, Haemostasis, Int J Cancer, Int J Clin Lab Res, J Cell Mol Med, J Clin Invest, J Immunol, Protein Eng

Pubblicazioni

Articoli su riviste con peer review	121
Libri	1
Capitoli libri in lingua inglese	14
Capitoli libri in italiano	14

Pubblicazioni dal 2000

- Ammollo CT, Semeraro F, Milella RA, Antonacci D, Semeraro N, and Colucci M. Grape intake reduces thrombin generation and enhances plasma fibrinolysis. Potential role of circulating procoagulant microparticles. *J Nutr Biochem* 2017, in corso di stampa.
- Tripodi A, Ammollo CT, Semeraro F, Colucci M, Malchiodi E, Verrua E, Ferrante E, Arnaldi G, Trementino L, Padovan L, Chantarangkul V, Peyvandi F and Mantovani G. Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. *Endocrine*. 2017;56:298-307.
- Semeraro F, Incampo F, Ammollo CT, Dellanoce C, Paoletti O, Testa S and Colucci M. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation. *Thromb Res*. 2016;138:22-9.
- Colucci M, Incampo F, Cannavo A, Menegatti M, Siboni SM, Zaccaria F, Semeraro N and Peyvandi F. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway. *J Thromb Haemost*. 2016;14:1603-14.
- Ammollo CT, Semeraro N, Carratu MR, Colucci M and Semeraro F. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran. *The Journal of pharmacology and experimental therapeutics*. 2016;356:305-13.
- Semeraro N, Ammollo CT, Semeraro F and Colucci M. Coagulopathy of Acute Sepsis. *Semin Thromb Hemost*. 2015;41:650-8.
- Ammollo CT, Zaccaria F, Visino F, Testa S, Semeraro N and Colucci M. Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding. *Br J Haematol*. 2015;168:911-3.
- Visino F, Zaccaria F, Semeraro N and Colucci M. A modified prothrombin time to measure the anticoagulant activity of dabigatran. *Thromb Res*. 2014;134:1368-9.
- Incampo F, Carrieri C, Semeraro N and Colucci M. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation. *Thromb Res*. 2014;134:1110-6.
- Incampo F, Carrieri C, Galasso R, Marino R, Ettore CP, Semeraro N and Colucci M. Co-administration of low molecular weight heparin enhances the profibrinolytic effect of warfarin through different mechanisms. *Thromb Res*. 2014;133:634-9.
- Belviso BD, Caliandro R, de Candia M, Zaetta G, Lopopolo G, Incampo F, Colucci M and Altomare CD. How a beta-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety:

- crystallography, fragment deconstruction study, and evaluation of antithrombotic properties. *Journal of medicinal chemistry*. 2014;57:8563-75.
- Semeraro F, Ammollo CT, Gils A, Declerck PJ and Colucci M. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a. *J Thromb Haemost*. 2013;11:2137-47.
- Incampo F, Carrieri C, Galasso R, Scaraggi FA, Di Serio F, Woodhams B, Semeraro N and Colucci M. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis. *J Thromb Haemost*. 2013;11:315-24.
- Carrieri C, Milella RA, Incampo F, Crupi P, Antonacci D, Semeraro N and Colucci M. Antithrombotic activity of 12 table grape varieties. Relationship with polyphenolic profile. *Food Chem*. 2013;140:647-53.
- Semeraro N, Ammollo CT, Semeraro F and Colucci M. Sepsis, thrombosis and organ dysfunction. *Thromb Res*. 2012;129:290-5.
- Semeraro F, Giordano P, Faienza MF, Cavallo L, Semeraro N and Colucci M. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1. *Thromb Haemost*. 2012;108:311-7.
- Milella RA, Antonacci D, Crupi P, Incampo F, Carrieri C, Semeraro N and Colucci M. Skin extracts from 2 Italian table grapes (Italia and Palieri) inhibit tissue factor expression by human blood mononuclear cells. *J Food Sci*. 2012;77:H154-9.
- Colucci M and Semeraro N. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation. *Thromb Res*. 2012;129:314-9.
- Cariello M, Simone S, Loverre A, Gigante M, Incampo F, Pietanza S, Colucci M, Schena FP, Gesualdo L, Grandaliano G and Pertosa G. Coagulation activation is associated with nicotinamide adenine dinucleotide phosphate oxidase-dependent reactive oxygen species generation in hemodialysis patients. *Antioxid Redox Signal*. 2012;16:428-39.
- Carrieri C, Galasso R, Semeraro F, Ammollo CT, Semeraro N and Colucci M. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood. *J Thromb Haemost*. 2011;9:154-62.
- Semeraro N, Ammollo CT, Semeraro F and Colucci M. Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. *Mediterranean journal of hematology and infectious diseases*. 2010;2:e2010024.
- Paparella D, Semeraro F, Scrascia G, Galeone A, Ammollo CT, Kounakis G, de Luca Tupputi Schinosa L, Semeraro N and Colucci M. Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses. *Ann Thorac Surg*. 2010;89:421-7.

- Ammollo CT, Semeraro F, Incampo F, Semeraro N and Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. *J Thromb Haemost.* 2010;8:790-8.
- Semeraro F, Ammollo CT, Semeraro N and Colucci M. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. *Haematologica.* 2009;94:819-26.
- Rossiello MR, Rotunno C, Coluccia A, Carratu MR, Di Santo A, Evangelista V, Semeraro N and Colucci M. Ochratoxin A inhibits the production of tissue factor and plasminogen activator inhibitor-2 by human blood mononuclear cells: another potential mechanism of immune-suppression. *Toxicol Appl Pharmacol.* 2008;229:227-31.
- Colucci M, Cattaneo M, Martinelli I, Semeraro F, Binetti BM and Semeraro N. Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. *J Thromb Haemost.* 2008;6:1571-7.
- Semeraro F, Piro D, Rossiello MR, Ammollo T and Colucci M. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots. *Thromb Haemost.* 2007;98:1208-14.
- Altomare DF, Rotelli MT, Pentimone A, Rossiello MR, Martinelli E, Guglielmi A, De Fazio M, Marino F, Memeo V, Colucci M and Semeraro N. Tissue factor and vascular endothelial growth factor expression in colorectal cancer: relation with cancer recurrence. *Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland.* 2007;9:133-8.
- Binetti BM, Rotunno C, Tripodi A, Asti D, Semeraro F, Semeraro N and Colucci M. Hyperprothrombinaemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis. *Thromb Haemost.* 2006;95:606-11.
- Rossiello MR, Momi S, Caracchini R, Giannini S, Guglielmini G, Monopoli A, Ongini E, Semeraro N, Colucci M and Gresele P. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. *J Thromb Haemost.* 2005;3:2554-62.
- Colucci M, Rossiello MR, Pentimone A, Berloco P, Russo F, Di Leo A and Semeraro N. Changes in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with *Helicobacter pylori* infection. *Thromb Res.* 2005;116:471-7.
- Colucci M, Binetti BM, Tripodi A, Chantarangkul V and Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. *Blood.* 2004;103:2157-61.
- Colucci M, Simioni P, Piro D, Prandoni P, Pagnan A and Semeraro N. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia. *Haematologica.* 2003;88:1383-9.

- Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N and Gresele P. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. *Hepatology*. 2003;38:230-7.
- Altomare DF, Rotelli MT, Memeo V, Martinelli E, Guglielmi A, DeFazio M, D'Elia G, Pentimone A, Colucci M and Semeraro N. [Expression of tissue factor and vascular endothelial growth factor in colorectal carcinoma]. *Tumori*. 2003;89:5-6.
- Colucci M, Pentimone A, Binetti BM, Cramarossa M, Piro D and Semeraro N. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin. *Thromb Haemost*. 2002;88:282-7.
- Montemurro P, Barbuti G, Dundon WG, Del Giudice G, Rappuoli R, Colucci M, De Rinaldis P, Montecucco C, Semeraro N and Papini E. Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells. *The Journal of infectious diseases*. 2001;183:1055-62.
- Colucci M, Stramaglia AM, Mascolo E, Napoleone E, Lorenzet R and Semeraro N. Monocytes, but not endothelial cells, downregulate the anticoagulant activity of activated protein C. *Br J Haematol*. 2001;112:519-26.
- Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J and Semeraro N. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. *Thromb Haemost*. 2001;85:661-6.
- Rossiello MR, Italia A, Stramaglia AM, Gesualdo L, Grandaliano G, Schena FP, Semeraro N and Colucci M. Fibrin down-regulates LPS- and PMA-induced tissue factor expression by blood mononuclear cells. *Thromb Haemost*. 2000;84:453-9.